From a Soviet Space Program LabTo the Most-Studied Nootropic in Russia
A synthetic heptapeptide with 40 years of research, clinical registration in Russia, and BDNF upregulation as its core mechanism.
For In Vitro Research Applications Only
Scroll to reveal the Semax sequence
What Is Semax?
Semax is a synthetic heptapeptide analogue of ACTH(4-10) developed at Russia's Institute of Molecular Genetics, with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It upregulates BDNF (brain-derived neurotrophic factor) and is studied for cognitive enhancement, neuroprotection, stroke recovery, and anxiety reduction. The compound received state registration as a medicinal preparation in Russia in 1994, giving it more than 30 years of post-registration clinical use.
BDNF upregulationis the most consistently documented mechanism. BDNF is the primary growth factor for synapse formation, neuroplasticity, and neuron survival. Higher BDNF means better neuroplasticity: the brain's ability to rewire itself in response to learning and experience. A second mechanism involves dopamine and serotonin system modulation: Semax affects the density and sensitivity of receptors for both neurotransmitters, enhancing the responsiveness of the neural circuits that drive focused attention and motivation. Neuroprotection is a third documented effect, particularly relevant to its original clinical purpose in stroke and cerebral ischemia models, where Semax significantly reduces neuronal death through BDNF-mediated survival signaling.
“Higher BDNF means better neuroplasticity: the brain’s ability to rewire itself in response to learning and experience.”
- Semax Research Literature, 2007
40+
Years of Research
1994
Clinical Registration (Russia)
250+
Published Studies
Scroll to build the Semax sequence
What the Research Actually Shows
Three findings from 40 years of Semax research that are consistent across independent labs.
By the Numbers
0+
Published Studies
0+
Years of Research
0
Clinical Registration
0
Research Areas
What the Semax Research Literature Actually Contains
40+ years of published research. Six active areas of scientific investigation.
Published Studies
peer-reviewed publications in research literature (PubMed, 2024)
BDNF Upregulation
Semax consistently upregulates BDNF in hippocampal and cortical tissue in published studies. BDNF is the primary growth factor for synapse formation, neuroplasticity, and neuron survival. This mechanism is the foundation of Semax's neuroprotective and cognitive enhancement research.
View Published StudiesStroke Recovery and Neuroprotection
Semax is registered in Russia for ischemic stroke and transient ischemic attacks. Clinical trials have documented neuroprotective effects in models of cerebral ischemia. It is the original and most clinically developed application of the compound.
View Published StudiesCognitive Performance Enhancement
Multiple studies in healthy human subjects have examined Semax's effects on attention, working memory, and information processing speed. Results have shown improvement on cognitive performance measures in controlled research settings.
View Published StudiesMonoamine System Modulation
Semax modulates dopaminergic and serotonergic receptor density and sensitivity in published research. Electrophysiological studies document changes in neural circuit activity. This mechanism contributes to the compound's effects on motivation and cognitive engagement.
View Published StudiesAnxiety and Stress Research
Secondary to its cognitive enhancement properties, Semax shows anxiolytic effects in preclinical models. Unlike classic anxiolytics, these effects occur without sedation. Research suggests they may derive from the same BDNF-mediated neuroplasticity pathway.
View Published StudiesSafety and Tolerance Profile
Semax has been in clinical use in Russia since 1994. The published literature, including controlled clinical trials, reports acceptable tolerability at studied doses. No significant adverse effects have been documented in the peer-reviewed literature at research-relevant doses.
View Published Studies40 Years of Cognitive Peptide Research
Semax was synthesized at the Institute of Molecular Genetics in Moscow in 1982. Here is how four decades of published research have unfolded.
Soviet researchers at the Institute of Molecular Genetics begin studying ACTH fragments for cognitive and neuroprotective properties. ACTH(4-10) is identified as having CNS effects independent of hormonal activity.
Russian Academy of Sciences
Semax is synthesized: the ACTH(4-10) fragment is extended with a proline-glycine-proline tail to improve stability and CNS penetration. The heptapeptide sequence Met-Glu-His-Phe-Pro-Gly-Pro is established.
First controlled clinical trials begin in Russia for ischemic stroke recovery. Human safety and efficacy data begins to accumulate in the Russian medical literature.
Semax receives state registration in Russia as a medicinal preparation for ischemic stroke, transient ischemic attacks, and cognitive impairment conditions. Clinical use begins.
Russian Ministry of Health
Research expands beyond stroke to cognitive enhancement in healthy subjects. Studies examine attention, working memory, and information processing speed improvements.
BDNF upregulation confirmed as the primary mechanism across multiple independent research groups. Hippocampal and cortical neurotrophic effects documented in animal models.
International research community engagement increases. Dopaminergic and serotonergic modulation mechanisms documented alongside BDNF pathway research.
Over 250 peer-reviewed publications reference Semax in the research literature. Research continues across neuroprotection, cognitive enhancement, and anxiety applications.
Ready to review the full compound specifications and batch documentation?
View Semax Product Specifications →Not All Research Peptides Are the Same.
Purity. Verification. Transparency. Here is what we test for, and how you can verify it yourself.
When you order a research compound, you need to know exactly what you are getting. Impurities change experimental outcomes. Inconsistent purity means inconsistent data. This is why testing is not optional. It is the foundation of good research.
Every batch from Blackwell Biolabs is independently verified by a certified third-party laboratory before it ships. We test for purity, identity, sterility, and endotoxin levels. You do not have to take our word for it; every Certificate of Analysis is publicly available.
% Minimum Purity
peer-reviewed publications in research literature (PubMed, 2024)
Verified by HPLC (high-performance liquid chromatography), the gold standard analytical method for peptide purity assessment. Every batch. No exceptions.
Third-Party Tested
Independent laboratory analysis, not self-reported. COA (Certificate of Analysis) documents the exact test results, test method, and testing lab name and accreditation.
Mass Spectrometry ID
Synthesized in the United States and independently verified by third-party HPLC and mass spectrometry on every batch, confirming molecular identity and purity before release.
Lyophilized Powder
Bacterial endotoxin testing via LAL (Limulus Amebocyte Lysate) assay. Lyophilized powder format ensures maximum stability and shelf life for research applications.
Independent Testing. No Compromises.
Certificates of Analysis: Available for Every Batch
Our COAs include: HPLC chromatogram, Purity percentage, Molecular weight confirmation, Batch number, Testing date, Independent lab name and accreditation number
Working With a Physician on Your Research Protocol?
Some researchers work alongside licensed medical professionals. We make that connection easy.
The science of hormonal health optimization has advanced significantly over the past two decades. More medical professionals now offer evidence-informed, physician-supervised approaches to hormonal wellness.
Our clinical consultation team connects you with licensed professionals who specialize in this space. The initial eligibility review is free, no commitment, no pressure. Just an informed conversation with someone who understands the science.
This is not a replacement for your primary care physician. It is a resource for those who want to explore physician-supervised hormonal health pathways with professionals who are current on the research.
Speak with a licensed professional. No commitment required.
Sourcing Inquiries
Questions about quality standards, COAs, or procurement? (808) 644-0634 Text or call